Section Arrow
Quote
NAMS.NASDAQ
- NewAmsterdam Pharma Company NV
Quotes are at least 15-min delayed:2025/07/20 18:29 EDT
Regular Hours
Last
 22.2
+0.22 (+1.00%)
Day High 
22.62 
Prev. Close
21.98 
1-M High
22.75 
Volume 
951.57K 
Bid
18.99
Ask
22.9
Day Low
21.745 
Open
21.98 
1-M Low
17.63 
Market Cap 
2.47B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 21.06 
20-SMA 19.7 
50-SMA 19.31 
52-W High 27.29 
52-W Low 14.06 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.84/-2.13
Enterprise Value
2.47B
Balance Sheet
Book Value Per Share
6.92
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
45.56M
Operating Revenue Per Share
0.13
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
NCNANuCana plc0.0477+0.0009+1.92%-- 
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Quotes are at least 15-min delayed：2025/07/20 18:29 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.